
Cufryth-LS 2.5mg/30mg/50mg Syrup
Marketer
Penryth Labs Private Limited
Salt Composition
Levosalbutamol (2.5mg) + Ambroxol (30mg) + Guaifenesin (50mg)
Overview Cufryth-LS 2.5mg/30mg/50mg Syrup
LysoCough 2.5mg/30mg/50mg syrup is indicated for managing coughs accompanied by phlegm. It facilitates mucus clearance from the nasal passages, trachea, and lungs, easing expectoration. It also alleviates symptoms such as rhinorrhea, sneezing, pruritus, and lacrimation. LysoCough 2.5mg/30mg/50mg syrup should be administered as directed by your physician, with or without food. Dosage is individualized based on your response and condition. Continue treatment for the prescribed duration; premature cessation may lead to symptom recurrence and disease exacerbation. Inform your healthcare provider of all other medications you are using, as interactions are possible. Commonly reported adverse effects include vertigo, emesis, altered taste perception, diarrhea, cephalalgia, and cutaneous eruptions. Most are transient and self-limiting. Report any concerning side effects immediately. Drowsiness is a potential side effect; avoid activities requiring alertness until its impact is known. Alcohol consumption should be avoided due to potential additive sedative effects. Self-medication and sharing this medication are strongly discouraged. Adequate hydration is recommended during treatment. Disclose pregnancy, pregnancy planning, or breastfeeding to your doctor before commencing therapy. Kidney or liver impairment should also be reported to ensure appropriate dosage adjustment.
Primary Ingredients of Cufryth-LS 2.5mg/30mg/50mg Syrup
No text provided. Please provide the text you want me to rephrase.
Uses of Cufryth-LS 2.5mg/30mg/50mg Syrup
Productive cough
Major Benefits of Cufryth-LS 2.5mg/30mg/50mg Syrup:
Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment period. Always consult the product label for usage instructions prior to consumption. Use a measuring device for accurate dosing and ingest orally. Ensure thorough shaking before each use. Cufryth-LS 2.5mg/30mg/50mg Syrup can be consumed with or without food; however, consistent timing is recommended.
How to use Cufryth-LS 2.5mg/30mg/50mg Syrup:
Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment period. Always consult the product label for usage instructions prior to consumption. Use a measuring cup for accurate oral administration. Ensure thorough shaking before each dose. Cufryth-LS 2.5mg/30mg/50mg Syrup can be ingested with or without food; however, consistent timing is recommended.
How Cufryth-LS 2.5mg/30mg/50mg Syrup works:
Cufryth-LS Syrup, available in 2.5mg/30mg/50mg strengths, combines levosalbutamol, ambroxol, and guaifenesin to effectively manage coughs with phlegm. Levosalbutamol, a bronchodilator, opens the airways by relaxing airway muscles. Ambroxol, a mucolytic agent, liquefies mucus, facilitating easier expectoration. Guaifenesin, acting as an expectorant, reduces mucus viscosity, aiding its removal from the respiratory tract.
SAFETY ADVICE
AlcoholUNSAFE
Concomitant use of Cufryth-LS 2.5mg/30mg/50mg Syrup and alcohol can lead to increased sleepiness.
PregnancyCONSULT YOUR DOCTOR
Using Cufryth-LS 2.5mg/30mg/50mg Syrup during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a fetus. A physician will assess the advantages against possible hazards prior to prescribing. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
Lactation and the use of Cufryth-LS syrup (2.5mg/30mg/50mg) appear compatible. Available human data indicate minimal infant risk associated with maternal administration.
DrivingUNSAFE
Driving ability may be impaired by side effects associated with Cufryth-LS 2.5mg/30mg/50mg Syrup.
KidneyCAUTION
Patients with kidney impairment should use Cufryth-LS 2.5mg/30mg/50mg Syrup cautiously, potentially requiring dosage modification. Physician consultation is advised, as data on its use in this population is limited.
LiverCAUTION
Patients with liver impairment should use Cufryth-LS 2.5mg/30mg/50mg Syrup cautiously, potentially requiring dosage modification. Physician consultation is advised, as data on its use in this population is limited.
What if you forget to take Cufryth-LS 2.5mg/30mg/50mg Syrup :
Should you forget a dose of Cufryth-LS 2.5mg/30mg/50mg Syrup, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Cufryth-LS 2.5mg/30mg/50mg Syrup
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Treatment | Breathing |
